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Background: During the last 15 years, gabapentin has become an established component of 
postoperative pain treatment. Gabapentin has been employed in a wide range of doses, but little 
is known about the optimal dose, providing the best balance between benefit and harm. This 
systematic review with meta-analyses aimed to explore the beneficial and harmful effects of 
various doses of gabapentin administered to surgical patients.
Materials and methods: Data in this paper were derived from an original review, and the 
subgroup analyses were predefined in an International Prospective Register of Systematic 
Reviews published protocol: PROSPERO (ID: CRD42013006538). The methods followed 
Cochrane guidelines. The Cochrane Library’s CENTRAL, PubMed, EMBASE, Science Citation 
Index Expanded, Google Scholar, and FDA database were searched for relevant trials. Random-
ized clinical trials comparing gabapentin versus placebo were included. Four different dose 
intervals were investigated: 0–350, 351–700, 701–1050, and >1050 mg. Primary co-outcomes 
were 24-hour morphine consumption and serious adverse events (SAEs), with emphasis put 
on trials with low risk of bias. 
Results: One hundred and twenty-two randomized clinical trials, with 8466 patients, were 
included. Sixteen were overall low risk of bias. No consistent increase in morphine-sparing 
effect was observed with increasing doses of gabapentin from the trials with low risk of bias. 
Analyzing all trials, the smallest and the highest dose subgroups demonstrated numerically the 
most prominent reduction in morphine consumption. Twenty-seven trials reported 72 SAEs, 
of which 83% were reported in the >1050 mg subgroup. No systematic increase in SAEs was 
observed with increasing doses of gabapentin.
Conclusion: Data were sparse, and the small number of trials with low risk of bias is a major 
limitation for firm conclusions. Taking these limitations into account, we were not able to dem-
onstrate a clear relationship between the dosage of gabapentin and opioid-sparing or harmful 
effects. These subgroup analyses are exploratory and hypothesis-generating for future trialists.
Keywords: gabapentin, 1-(aminomethyl)cyclohexaneacetic acid, analgesic, postoperative pain 
management, dose effect
Introduction
During the last 15 years, gabapentin has become an established component of postop-
erative analgesia. Gabapentin has been employed in a wide range of doses, but little is 
known about the optimal dose, providing the best balance between benefit and harm 
in postoperative pain treatment.
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The number of published, dose-finding gabapentin trials 
in postoperative pain treatment is limited,1–11 and the results 
are inconsistent. It is well established, however, that oral 
gabapentin is absorbed in part by diffusion and in part by 
a carrier-mediated saturable transport mechanism system.13 
Thus, the bioavailability of oral gabapentin is not linear, but 
inversely dependent on the dose,14 ranging from ~60% for a 
300 mg dose to ~30% with doses of 1600 mg.14–16
Consequently, the optimal dosing of gabapentin, provid-
ing the best balance between benefit and harm, may not be 
obvious. In this post hoc subgroup analysis, we aimed to 
explore the relative effects of different doses of gabapentin 
on 24-hour morphine consumption, pain intensity, risk of 
serious adverse events (SAEs), and other adverse events.
We hypothesized that increasing doses of gabapentin 
would lead to increased reduction in 24-hour morphine con-
sumption and/or pain intensity, decreased adverse effects, and 
probably also increased risk of SAEs and other drug-specific 
adverse events. We realized, however, that the possible 
increase in beneficial and harmful effects with increasing 
doses of gabapentin would probably not be linear due to the 
nonlinear bioavailability of oral gabapentin.
Materials and methods
This review includes exploratory post hoc analyses from 
an original systematic review, employing the Cochrane 
Collaboration methodology. The protocol of the original 
PRISMA-compliant review is published in the Interna-
tional Prospective Register of Systematic Reviews website 
(www.crd.york.ac.uk/PROSPERO) with the registration no. 
CRD42013006538.17
Literature search
Our comprehensive search strategy was planned by a trial 
search coordinator and reported in the published sys-
tematic review18 and Supplementary material S1: search 
strategies.
The Cochrane Library’s CENTRAL, PubMed, EMBASE, 
Science Citation Index Expanded, Google Scholar, and FDA 
database, and reference lists of trials were searched for 
relevant trials. Unpublished trials were searched in relevant 
databases.
Randomized clinical trials comparing gabapentin versus 
placebo, irrespective of publication type, status, publication 
year, and language, were included. All non-English articles 
were translated to English. We updated the search strategy 
on April 12, 2016.
Data
MLF and one of the independent authors (AG, MSH, PLP, LN) 
screened the titles and abstracts, evaluated the risk of bias, and 
extracted data. Extracted data included article publication year, 
number of participants, surgical procedure, follow-up period 
and gabapentin dose administered, consumption of morphine 
(intravenous morphine based on equivalency, Supplementary 
material S2) and other nonopioid analgesics, pain intensity, 
and any adverse effects reported, including SAEs.
Pain intensity was reported in different scales in the 
original trials. All pain intensity scales using intensity scores 
between 0 and 10 were converted to the visual analog scale 
(VAS) 0–100 mm.
If data were incomplete or bias assessment was unclear, 
the corresponding author was contacted. This contact was 
repeated after 2 weeks in case of no response to initial contact. 
If the corresponding author did not reply, the involved bias 
domains were classified as unclear.
Assessment of risk of bias
The risk of bias assessment adhered to the Cochrane Hand-
book methodology.20 All the included trials were assessed as 
low, unclear, or high risk of bias using the six bias domains 
described in the handbook. The “other” bias domain consisted 
of financial and confirmatory bias evaluations.21 Any difference 
in evaluations between authors on any part of the data extrac-
tion and evaluations process was solved by OM, JBD, or JW.
It was protocolled that the review and conclusions would 
primarily be based on trials with low risk of bias.
Small trial size
This post hoc analysis assessed the number of patients 
included in each original trial as defined in the original sys-
tematic review.18 Trials with less than 50 participants were 
defined as small trials, trials with more than 50 participants 
in each group formed the second group, and the trials with 
more than 200 participants made up the final group.
Analyses
The dose treatments of gabapentin were divided into four 
groups: 0–350, 351–700, 701–1050, and more than 1050 mg. 
The defined groups represent the four most commonly used 
dose treatments in gabapentin research, which are 300, 600, 
900, and 1200 mg.
All doses are considered as 24-hour treatments, regardless 
of single or multiple administrations, pre- or postoperative 
treatments, or the duration of the treatment.
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If an original trial investigated more than one dose, the 
control group receiving placebo was divided into the corre-
sponding number of intervention groups. The trials in which 
the divided control groups included less than 20 participants 
were excluded. The individual dose-finding trials were 
counted as one trial in all summary statistics. Whenever the 
trials were included in cumulative analyses, the trials were 
viewed as separate trials.
Outcomes
Twenty-four-hour morphine consumption represented the 
beneficial primary outcome, and SAEs represented the 
harmful primary outcome. SAEs were classified according 
to the International Conference of Harmonization – Good 
Clinical Practice definitions: medical events being either 
life-threatening, resulting in death, disability, or significant 
loss of function, or causing hospital admission or prolonged 
hospitalization.18
The secondary outcomes were divided into beneficial 
outcomes: reduction in early (6-hour) and late (24-hour) 
pain postoperatively, both at rest and during mobilization, 
and harmful outcomes: all other adverse events.
Statistical analysis
Review Manager (RevMan; computer program), Version 
5.1.6 was used in the cumulated analyses and subgroup 
analyses.
The handling of median and range (or interquartile range), 
longer ordinal scales, and dichotomous data, examination 
of heterogeneity, employment of fixed- or random-effect 
models, Peto’s odds ratio (OR), and handling of few and rare 
events were done according to the International Prospective 
Register of Systematic Reviews published protocol and is 
described in the published PRISMA-compliant systematic 
review.17,18
If more than one trial was included in the outcome, the 
estimates were pooled in meta-analyses and test for subgroup 
analyses was performed using RevMan in which the method 
to test for subgroup differences was implemented.
All trials with one intervention group and one control 
group were included. Handling of trials investigating more 
than one dose is described above. The mean and standard 
deviations were divided according to the methodology 
described in the Cochrane Handbook.20,22
Trial sequential analysis (TSA) was used to adjust 
for sparse data and repetitive testing in the cumulative 
 analyses.23,24 Minimal relevant clinical differences were 
defined as in the published systematic review.18 TSA is only 
reported if the accrued information size was 5% or more of 
the required information size (RIS), since the TSA program 
is only able to report trial sequential monitoring boundaries 
if this is the case.
Results
In the original published systematic review, 19,137 titles were 
located, and after removal of duplicates, 16,303 titles were 
screened for inclusion and exclusion criteria. The original 
systematic review included 135 randomized clinical trials, 
including 3 observational studies.18
For the purpose of this review, the 3 observational studies, 
and 10 dose-finding trials with less than 20 patients in the 
split control groups, were excluded,1–4,6,7,8,10,11,25 leaving 122 
trials with 8466 participants for analyses (Supplementary 
material S3: trial characteristics).5,9,19,25–143
Trial characteristics
In these analyses, 16 trials demonstrated overall low risk 
of bias,5,9,35,41,55,58,62,76,91,95,107,108,127,128,140 36 trials showed 
unclear risk of bias,25,26,30,32,34,36,38,40,42,45,51,52,54,57,59,67,69,70, 
73–75,79,84,86,88,99,100,101,103,119,122,124,125,130,139,141,143, and 70 showed 
high risk of bias (Figure 1; Supplementary material S4: risk 
of bias graph).6,8,12,19,27–29,31,33,37,39,43,44,46–50,53,56,60,61,63–66,71,72,77,78, 
80–83,85,87,88,90,92–94,97,99,102,105,106,109–118,120,121,123,124,126,129,131,132,134–138,142
We found that 105 trials were “small trials”,12,25–27, 
29–43,45,47–61,63,65–75,77–84,86–94,96–101,104–106,109–127,131–142 14 trials 
included more than 50 participants in each group,9,19,28,44,46,62
,76,85,95,107,108,128,130,143 and only 2 trials included more than 200 
participants.5,102
Treatment with gabapentin included both single-dose 
(84 trials)9,12,25–29,31–36,40–45,47,49–52,56,58,59,61,63,65–67,69–73,75–78,82–86, 
88,90–94,96,97,99,102–106,109,111–118,120–122,124,125,128–131,133,136,138,139,143 
and multiple-dose administration (38 trials).5,30,37–39,46,48, 
53–55,57,60,62,68,74,79–81,89,95,98,100,101,107,108,110,119,123,126,127,132,134,135,137,140–142 
For further information about the individual trials, see 
Supplementary material S3: trial characteristics.
Primary outcomes
Total 24-hour morphine consumption
Sixty-five trials with 4851 patients reported 24-hour opioid 
consumption, and 15 trials (1318 participants) were classified 
as overall low risk of bias.
Trials with low risk of bias
In the 0–350 mg subgroup, a reduction in 24-hour mor-
phine consumption of 2.2 mg (0.1, 4.4; p=0.04)9,140 was 
reported with gabapentin versus control. The 351–700 mg 
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subgroup demonstrated a reduction of 3.4 mg (0.9, 8.5; 
p=0.12),9,91,95,96,107,108,128 the 701–1050 mg subgroup an 
increase in consumption of 24-hour morphine consump-
tion of 1.1 mg (0.3, 2.0; p=0.01),5,41,55,58,62 and the subgroup 
>1050 mg reported a reduction of 2.9 mg (−1.1, 6.9; p=0.2), 
as shown in Table 1 and Figure 2.5,41,55,62
The test for subgroup differences was significant for the 
701–1050 mg subgroup compared with the other subgroups 
(p=0.002), but no systematic increase in morphine-sparing 
effect was observed with increasing doses of gabapentin. 
With TSA, half the subgroup meta-analyses reached the 
futility area with the predefined minimal clinical difference 
and alpha and beta, while the other half did not report firm 
results (Table 1).
All trials
All subgroups demonstrated a reduction in 24-hour morphine 
consumption (Table 2 and Figure 3). Differences between the 
different dose intervals were statistically significant in test 
for subgroup differences between the 350–700, 701–1050 
mg, and >1050 mg subgroups. The 0–350 mg subgroup and 
the >1050 mg subgroup demonstrated numerically most 
pronounced reduction in morphine consumption, but no 
systematic increase in morphine-sparing effect was observed 
with increasing doses of gabapentin. Only the meta-analysis 
for the subgroup 701–1050 did not report firm evidence 
according to TSA (Table 1).
SAE
Twenty-seven trials with 1958 participants reported 72 SAEs, 
of which 83% were reported in the >1050 mg subgroup. 
Of the 27 trials, 8 were classified as overall low risk of 
bias,5,9,41,62,76,107,128,140 and these 8 trials reported more than half 
the SAEs. The trials with overall low risk of bias reported the 
following SAEs: death, vein thrombosis, pneumonia, wound 
infection, admission to intensive care unit, and prolonged 
hospital stay.
Trials with low risk of bias
In the 0–350 mg subgroup,9,140 Peto’s OR and TSA were not 
estimable. In the remaining subgroups, the risk of SAEs was: 
351–700 mg subgroup: OR 0.9 (0.2, 3.4; p=0.85)9,76,107,128; 
700–1050 mg subgroup: OR 0.6 (0.04, 8.6; p=0.70)5; and 
>1050 mg subgroup: OR 2.0 (0.9, 4.5; p=0.1).5,41,62 No sub-
group differences were demonstrated for this outcome, and 
no systematic increase in SAEs was observed with increasing 
doses of gabapentin (Figure 4). It was only possible to con-
duct TSA on two subgroups (351–700 and >1050 mg), and 
both subgroups had less than 20% of RIS and none reported 
firm evidence (Table 1).
All trials
None of the gabapentin subgroups demonstrated statisti-
cally significant increases in SAEs compared with controls 
(Figure 5). No significant differences between the different 
dose intervals were demonstrated, and no systematic increase 
in SAEs was observed with increasing doses of gabapentin 
(Table 2). TSA showed that none of the three subgroups, 
351–700, 701–1050, and >1050 mg, reached firm evidence, 
nor did they reach more than 5% of RIS.
Secondary outcomes
Pain intensity
Little data have been reported from trials with low risk of 
bias, limiting the reliability of the test for subgroup dif-
ferences. No consistent dose-related trends or subgroup 
Figure 1 Bias evaluation of the six bias domains.
Note: The “other” bias domain consists of an evaluation of financial and confirmatory bias.
Random sequence generation (selection bias)
Allocation concealment (selection bias)
Blinding of participants and personnel (performance bias)
Blinding of outcome assessment (detection bias)
Incomplete outcome data (attrition bias)
Selective reporting (reporting bias)
Other bias
0% 25% 50%
High risk of biasUnclear risk of biasLow risk of bias
75% 100%
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Dose-related effect of gabapentin
differences were demonstrated in the all trials estimates 
(Table 2; Supplementary material S5–S12: forest plots of 
pain intensities).
Adverse events
No consistent dose-related trends or subgroup differences 
were demonstrated either in data from trials with low risk 
of bias or in the all trials estimates (Table 3). None of the 
meta-analyses of trials with low risk of bias reporting risk of 
AE reached firm evidence according to TSA (Supplementary 
material S13–S20: forest plot of AE).
Discussion
In this review, we aimed to explore the effect of increasing 
doses of gabapentin on postoperative morphine consump-
tion, SAEs, pain intensity, and adverse events in four groups 
of trials that included the most commonly used doses of 
gabapentin for perioperative pain management: 300, 600, 
900, and 1200 mg.
For the primary beneficial outcome, 24-hour morphine 
consumption, no consistent increase in morphine-sparing 
effect was observed with increasing doses of gabapentin, 
either in the analysis of trials with low risk of bias or in the 
all trials analysis. On the contrary, the smallest (0–350 mg) 
and the largest (>1050 mg) dose regimens demonstrated 
comparable and the most pronounced reduction in morphine 
consumption in the all trials analysis.
Only few SAEs were reported, limiting any reliable 
conclusion on this outcome. Of 72 stated SAEs, 83% were 
reported in the >1050 mg subgroup, indicating an increased 
risk of SAEs with increasing doses. Of the 27 trials reporting 
SAEs, 10 were classified as overall low risk of bias, and these 
10 trials reported more than half the SAEs.
For the secondary outcomes, pain intensity and adverse 
events, no consistent dose-related trends or subgroup differ-
ences were demonstrated, either in data from trials with low 
risk of bias or in the all trials estimates.
We could not find any clear indication of a dose-related 
effect of gabapentin. A possible explanation may by the fact 
that higher doses of gabapentin lead to relatively smaller 
increases in blood concentrations because of the saturable 
absorption of gabapentin after oral administration.14,15,145 
This may potentially provide an upper limit to the effect of 
beneficial outcomes and adverse events. However, none of 
our results indicated a clear upper limit or difference between 
subgroups, confirming this hypothesis. The nonlinear absorp-
tion may be the main reason of the less-predictable clinical 
effect of increased doses, but other explanations also have 
to be considered.
The analgesic effect of gabapentin is considered to be 
related to its antihyperalgesic properties, as demonstrated 
for both single and multiple dosing in human volunteer 
pain models.146,147 In such models, gabapentin did not affect 
nociceptive pain per se.146–148 Furthermore, gabapentin 
demonstrated dose-dependent antihyperalgesic effects in rat 
pain models,149 which, however, has not been investigated in 
humans. It is, therefore, unknown if increasing doses of gaba-
pentin display increasing antihyperalgesic effects in humans, 
and if such a dose–response relationship is linear. This 
may contribute significantly to the shortcoming of detect-
ing a dose–response effect in postoperative pain patients. 
Furthermore, postoperative pain is related to multiple pain 
mechanisms, of which hyperalgesia is only one. It is, though, 
unknown how important the hyperalgesic component is for 
the total sum of experienced pain. This may, in part, also 
explain the shortcomings of detecting a dose–response rela-
tionship for postoperative gabapentin treatment.
The optimal dose for postoperative pain treatment has 
been investigated in a few original clinical trials.2–11,143 The 
study by Van Elstraete et al150 found a relatively high median 
effective analgesic dose of 21.7 mg/kg gabapentin in spinal 
fusion surgery. Considering this result, it is possible that 
the investigated doses, in general, are too low for analgesic 
efficacy, although higher doses (>1200 mg) most likely will 
produce profound adverse effects. 
Most included trials were small in size, and 86% of the 
trials included less than 50 participants in each group, which 
can be a limitation. The large number of small-sized trials 
leads to repetitive testing in the cumulative meta-analyses, 
increasing the risk of random error. Accordingly, we applied 
TSA to compensate for this limitation. The majority of 
cumulative subgroup analyses of trials with low risk of bias 
did not reach firm evidence, or the RIS. This limits any firm 
evidence and conclusions. In addition, the lack of data may 
cause a type II error.
The strengths of these subgroup analyses are related to 
the primary systematic review that was carried out using 
Cochrane methodology and reported according to PRISMA 
guidelines. All trials were critically assessed using the 
Cochrane bias evaluation tools, and the risk of random 
error was assessed using TSA to adjust for sparse data and 
repetitive testing.
However, there are substantial limitations to our results. 
The conclusions based on our results are generally weakened 
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Dose-related effect of gabapentin
by the low number of trials classified as overall low risk of 
bias, which limits the test for subgroup differences, and pooled 
estimates in meta-analyses. The few number of trials with low 
risk of bias means that all trials estimates must be factored into 
the evaluation and interpretation of these subgroup analyses. 
It is well described that estimates from trials with unclear and 
high risk of bias have an inherent risk of overestimating ben-
eficial outcomes and underestimating harmful events, which 
must be taken into account upon conclusions and further use 
in future hypothesis based on these analyses.144
Few of the included trials reported SAEs, and most of 
the trials exhibited a short follow-up period, further limiting 
the analyses exploring the risks of gabapentin treatment.18
Further, this review consists of post hoc analyses, which 
limit the reliability of the results. The subgroups of our 
analyses must be interpreted as observational studies, with 
the inherent limitations of such studies: Confounding by other 
study characteristics may bias the analyses. Some of these 
study characteristics, such as gabapentin with other nono-
pioid analgesics, have been explored in the original work,18 
while the effect of gabapentin in six different  procedures was 
explored in a separate published article finding no difference 
between surgical procedures on beneficial and harmful out-
comes from trials with overall low risk of bias.151
Our post hoc analysis was meant to explore the dose 
effect of gabapentin in published randomized clinical trials, 
since there is no previously published systematic on the topic. 
Based on the combined analyses, we cannot recommend a 
specific dose or regimen, if any, for perioperative gabapentin 
treatment. We hope that our analyses may inspire the hypoth-
eses of future trials.
Conclusion
Data were sparse in all subgroups, and the small number of 
trials with low risk of bias is a major limitation for firm con-
clusions. Taking these limitations into account, we were not 
able to demonstrate a clear relationship between the dosage 
of gabapentin and opioid-sparing or harmful effects. Numeri-
cally, most SAEs were reported in the higher dosing groups, 
and trials with low risk of bias reported the most SAEs. These 
subgroup analyses are exploratory and hypothesis-generating 
for future trialists.
Figure 2 Forest plot of 24-hour morphine consumption from trials with overall low risk of bias.
Abbreviations: df, degrees of freedom; CI, confidence interval; SD, standard deviation; IV, inverse variance.
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Fabritius et al
Figure 3 Forest plot of 24-hour morphine consumption from all trials estimates regardless of bias evaluation.
Abbreviations: df, degrees of freedom; CI, confidence interval; SD, standard deviation; IV, inverse variance.
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